Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma : multicentre, retrospective cohort study

© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd..

BACKGROUND: The Mayo protocol for liver transplantation in patients with unresectable perihilar cholangiocarcinoma is based on strict selection and neoadjuvant chemoradiotherapy. The role of neoadjuvant chemoradiotherapy in this scenario remains unclear. The aim of this study was to compare outcomes after transplantation for perihilar cholangiocarcinoma using strict selection criteria, either with or without neoadjuvant chemoradiotherapy.

METHODS: This was an international, multicentre, retrospective cohort study of patients who underwent transplantation between 2011 and 2020 for unresectable perihilar cholangiocarcinoma using the Mayo selection criteria and receiving neoadjuvant chemoradiotherapy or not receiving neoadjuvant chemoradiotherapy. Endpoints were post-transplant survival, post-transplant morbidity rate, and time to recurrence.

RESULTS: Of 49 patients who underwent liver transplantation for perihilar cholangiocarcinoma, 27 received neoadjuvant chemoradiotherapy and 22 did not. Overall 1-, 3-, and 5-year post-transplantation survival rates were 65 per cent, 51 per cent and 41 per cent respectively in the group receiving neoadjuvant chemoradiotherapy and 91 per cent, 68 per cent and 53 per cent respectively in the group not receiving neoadjuvant chemoradiotherapy (1-year hazards ratio (HR) 4.55 (95 per cent c.i. 0.98 to 21.13), P = 0.053; 3-year HR 2.07 (95 per cent c.i. 0.78 to 5.54), P = 0.146; 5-year HR 1.71 (95 per cent c.i. 0.71 to 4.09), P = 0.229). Hepatic vascular complications were more frequent in the group receiving neoadjuvant chemoradiotherapy compared with the group not receiving neoadjuvant chemoradiotherapy (nine of 27 versus two of 22, P = 0.045). In multivariable analysis, tumour recurrence occurred less frequently in the group receiving neoadjuvant chemoradiotherapy (HR 0.30 (95 per cent c.i. 0.09 to 0.97), P = 0.044).

CONCLUSION: In selected patients undergoing liver transplantation for perihilar cholangiocarcinoma, neoadjuvant chemoradiotherapy resulted in a lower risk of tumour recurrence, but was associated with a higher rate of early hepatic vascular complications. Adjustments in neoadjuvant chemoradiotherapy reducing the risk of hepatic vascular complications, such as omitting radiotherapy, may further improve the outcome in patients undergoing liver transplantation for perihilar cholangiocarcinoma.

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:7
Enthalten in:	BJS open - 7(2023), 2 vom: 07. März

Sprache:	Englisch

Beteiligte Personen:

Hoogwater, Frederik J H [VerfasserIn] Kuipers, Hendrien [VerfasserIn] de Meijer, Vincent E [VerfasserIn] Maulat, Charlotte [VerfasserIn] Muscari, Fabrice [VerfasserIn] Polak, Wojciech G [VerfasserIn] van Hoek, Bart [VerfasserIn] Jézéquel, Caroline [VerfasserIn] Alwayn, Ian P J [VerfasserIn] Ijzermans, Jan N M [VerfasserIn] Mohkam, Kayvan [VerfasserIn] Mabrut, Jean-Yves [VerfasserIn] Van Vilsteren, Frederike G I [VerfasserIn] Adam, Jean-Philippe [VerfasserIn] Chiche, Laurence [VerfasserIn] Chebaro, Alexandre [VerfasserIn] Boleslawski, Emmanuel [VerfasserIn] Dubbeld, Jeroen [VerfasserIn] Murad, Sarwa Darwish [VerfasserIn] Rayar, Michel [VerfasserIn] Porte, Robert J [VerfasserIn]

Links:	Volltext

Themen:	Journal Article Multicenter Study

Anmerkungen:	Date Completed 11.04.2023 Date Revised 14.04.2023 published: Print Citation Status MEDLINE

doi:	10.1093/bjsopen/zrad025

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM355370611